BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 15249855)

  • 1. Differential expression of HMGA1 and HMGA2 in dermatofibroma and dermatofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor XIIIa immunoreactivity.
    Li N; McNiff J; Hui P; Manfioletti G; Tallini G
    Am J Dermatopathol; 2004 Aug; 26(4):267-72. PubMed ID: 15249855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34.
    Kim HJ; Lee JY; Kim SH; Seo YJ; Lee JH; Park JK; Kim MH; Cinn YW; Cho KH; Yoon TY
    Br J Dermatol; 2007 Aug; 157(2):319-24. PubMed ID: 17596171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD34 and factor-XIIIa immunoreactivity in dermatofibrosarcoma protuberans and dermatofibroma.
    Goldblum JR; Tuthill RJ
    Am J Dermatopathol; 1997 Apr; 19(2):147-53. PubMed ID: 9129699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIIIa.
    Kahn HJ; Fekete E; From L
    Hum Pathol; 2001 Jan; 32(1):50-6. PubMed ID: 11172295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Differences of the molecular phenotypes and the histogenesis between dermatofibroma and dermatofibrosarcoma protuberans].
    Xiong Y; Guo H; Zhang S; Zhang B; Li T
    Beijing Da Xue Xue Bao Yi Xue Ban; 2008 Aug; 40(4):395-400. PubMed ID: 18677387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of nestin in dermatofibrosarcoma protuberans in comparison to dermatofibroma.
    Mori T; Misago N; Yamamoto O; Toda S; Narisawa Y
    J Dermatol; 2008 Jul; 35(7):419-25. PubMed ID: 18705829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical markers in fibrohistiocytic lesions: factor XIIIa, CD34, S-100 and p75.
    West KL; Cardona DM; Su Z; Puri PK
    Am J Dermatopathol; 2014 May; 36(5):414-9. PubMed ID: 24162384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of CD163 in dermatofibroma, cellular fibrous histiocytoma, and dermatofibrosarcoma protuberans: comparison with CD68, CD34, and Factor XIIIa.
    Sachdev R; Sundram U
    J Cutan Pathol; 2006 May; 33(5):353-60. PubMed ID: 16640542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGFBP7, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans.
    Li J; Yu Y; Yang Y; Wang L; Cao J; Liang X; Xiao X; Tu Y; Chen H
    J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):382-5. PubMed ID: 21492256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dermatofibroma and dermatofibrosarcoma protuberans: an immunohistochemical study reveals distinctive antigenic profiles.
    Hsi ED; Nickoloff BJ
    J Dermatol Sci; 1996 Jan; 11(1):1-9. PubMed ID: 8867761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD44 and hyaluronate in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans.
    Calikoglu E; Augsburger E; Chavaz P; Saurat JH; Kaya G
    J Cutan Pathol; 2003 Mar; 30(3):185-9. PubMed ID: 12641778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD34 and factor XIIIa in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans.
    Abenoza P; Lillemoe T
    Am J Dermatopathol; 1993 Oct; 15(5):429-34. PubMed ID: 7694515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study of CD117 expression in dermatofibrosarcoma protuberans and cellular dermatofibroma.
    Labonte S; Hanna W; Bandarchi-Chamkhaleh B
    J Cutan Pathol; 2007 Nov; 34(11):857-60. PubMed ID: 17944726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of CD34 and D2-40 in the Differentiation of Dermatofibroma and Dermatofibrosarcoma Protuberans.
    Sadullahoğlu C; Dere Y; Atasever TR; Öztop MT; Karaaslan Ö
    Turk Patoloji Derg; 2017; 1(1):223-227. PubMed ID: 28832078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When Immunohistochemistry Deceives Us: The Pitfalls of CD34 and Factor XIIIa Stains in Dermatofibroma and Dermatofibrosarcoma Protuberans.
    John AM; Holahan HH; Singh P; Handler MZ; Lambert WC
    Skinmed; 2017; 15(1):53-55. PubMed ID: 28270311
    [No Abstract]   [Full Text] [Related]  

  • 16. Expression of MMP-2, MMP-9 and MMP-11 in dermatofibroma and dermatofibrosarcoma protuberans.
    Chen YT; Chen WT; Huang WT; Wu CC; Chai CY
    Kaohsiung J Med Sci; 2012 Oct; 28(10):545-9. PubMed ID: 23089320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. D2-40, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans.
    Bandarchi B; Ma L; Marginean C; Hafezi S; Zubovits J; Rasty G
    Mod Pathol; 2010 Mar; 23(3):434-8. PubMed ID: 20062007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indeterminate fibrohistiocytic lesions of the skin: is there a spectrum between dermatofibroma and dermatofibrosarcoma protuberans?
    Horenstein MG; Prieto VG; Nuckols JD; Burchette JL; Shea CR
    Am J Surg Pathol; 2000 Jul; 24(7):996-1003. PubMed ID: 10895822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dermatofibrosarcoma protuberans: a tumour of nestin-positive cutaneous mesenchymal stem cells?
    Sellheyer K; Nelson P; Krahl D
    Br J Dermatol; 2009 Dec; 161(6):1317-22. PubMed ID: 19659472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors.
    Hanly AJ; Jordà M; Elgart GW; Badiavas E; Nassiri M; Nadji M
    Arch Pathol Lab Med; 2006 Jun; 130(6):831-4. PubMed ID: 16740036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.